Skip to content

Intellia Therapeutics, Inc.

NTLA · XNAS

CIK 1652130fmd_19AMT2RXJE4D6E1C2FN25YSBEWManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard

Coverage: Jan 01, 2015 to Sep 30, 2026, 47 periods

AI-written

A model wrote this from the company's own SEC filings and our standardized facts. It is not reported fact, not an analyst's estimate, not a rating and not investment advice. Every claim shows what it rests on.

Loading